Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Fulvestrant + NUV-422 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 29 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
NUV-422 | NUV422 | CDK2 Inhibitor 31 CDK4 Inhibitor 17 CDK6 Inhibitor 6 | NUV-422 inhibits CDK2/4/6, which may lead to cell cycle arrest and growth inhibition (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05191004 | Phase Ib/II | NUV-422 Fulvestrant + NUV-422 Fulvestrant | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Withdrawn | USA | 0 |